[1]李 果,王世进.阿帕替尼联合紫杉醇治疗复发性耐药型上皮性卵巢癌疗效观察[J].新乡医学院学报,2022,39(4):341-345.[doi:10.7683/xxyxyxb.2022.04.008]
 LI Guo,WANG Shijin.Efficacy of apatinib combined with paclitaxel in the treatment of recurrent drug-resistant epithelial ovarian cancer[J].Journal of Xinxiang Medical University,2022,39(4):341-345.[doi:10.7683/xxyxyxb.2022.04.008]
点击复制

阿帕替尼联合紫杉醇治疗复发性耐药型上皮性卵巢癌疗效观察
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年4
页码:
341-345
栏目:
临床研究
出版日期:
2022-04-05

文章信息/Info

Title:
Efficacy of apatinib combined with paclitaxel in the treatment of recurrent drug-resistant epithelial ovarian cancer
作者:
李 果王世进
(新乡医学院第一附属医院妇科,河南 卫辉 453100)
Author(s):
LI GuoWANG Shijin
(Department of Gynecology,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China)
关键词:
上皮性卵巢癌紫杉醇阿帕替尼糖类抗原125
Keywords:
epithelial ovarian cancerpaclitaxelapatinibcarbohydrate antigen 125
分类号:
R737.31
DOI:
10.7683/xxyxyxb.2022.04.008
文献标志码:
A
摘要:
目的 探讨阿帕替尼联合紫杉醇治疗复发性耐药型上皮性卵巢癌患者的临床疗效及不良反应。方法 选择2018年9月至2019年7月新乡医学院第一附属医院收治的复发性耐药型上皮性卵巢癌58例患者为研究对象,按照随机数字表法将患者分为观察组和对照组。对照组给予80 mg·m-2紫杉醇单药静脉滴注,第1天、第8天、第15天用药,每28 d重复1次;观察组患者在对照组基础上给予500 mg·d-1阿帕替尼,晨起空腹口服。2组患者均以3周为1个化学治疗周期,共治疗8个周期。比较2组患者的无进展生存期(PFS)、客观缓解率(ORR)和疾病控制率(DCR)。采用电化学发光法测定患者治疗前后血清中糖类抗原125(CA125)水平,应用常见不良事件评价标准分析不良反应,Karnofsky功能状态(KPS)评分评估患者的生存质量。结果 观察组2例化学治疗期间因出现与阿帕替尼相关的严重不良反应选择退出,1例自行停药;对照组2例转往其他医院治疗,1例改变化学治疗方案,2组各有26例完成全部治疗和评估。观察组和对照组患者ORR分别为53.85 %(14/26)、23.08%(6/26),DCR分别为92.31 %(24/26)、69.23 %(18/26);观察组患者ORR和DCR显著高于对照组(χ2=5.200、4.457,P<0.05)。观察组患者中位PFS为8.9个月,对照组患者中位PFS为6.9个月;观察组患者的中位PFS显著长于对照组(P<0.05)。2组患者治疗前血清中CA125水平比较差异无统计学意义 (P>0.05);治疗后,2组患者血清中CA125水平显著低于治疗前,观察组患者血清中CA125水平显著低于对照组(P<0.05)。治疗前,2组患者的KPS评分比较差异无统计学意义(P>0.05);治疗后,2组患者的KPS评分显著高于治疗前,观察组患者的KPS评分显著高于对照组(P<0.05)。2组患者治疗过程中胃肠道反应、乏力、手足综合征、贫血的发生率比较差异无统计学意义(P>0.05);观察者患者高血压的发生率高于对照组(χ2=0.002,P<0.05)。结论 阿帕替尼联合紫杉醇单药化学治疗可提高复发性耐药型上皮性卵巢癌患者的临床疗效。
Abstract:
Objective To investigate the clinical efficacy and adverse reactions of apatinib combined with paclitaxel in the treatment of patients with recurrent drug-resistant epithelial ovarian cancer.Methods A total of 58 patients with recurrent drug-resistant epithelial ovarian cancer admitted to the First Affiliated Hospital of Xinxiang Medical University from September 2018 to July 2019 were selected as study subjects,and the patients were randomly divided into observation group and control group according to random number table method.The patients in the control group was given 80 mg·m-2 of paclitaxel intravenously on the 1st,8th and 15th day,and which was repeated every 28 days;on the basis of the control group,the patients in the observation group were given apatinib with the dose of 500 mg·d-1,which was taken orally on an empty stomach in the morning;the patients in the two groups were treated for 8 cycles with 3 weeks as a chemotherapy cycle.The progression free survival (PFS),objective remission rate (ORR) and disease control rate (DCR) were compared between the two groups.The level of serum carbohydrate antigen 125 (CA125) of patients before and after treatment was measured by electrochemiluminescence method.The adverse reactions were analyzed by common adverse event evaluation standard.The quacity of life of patients was evaluated by Karnofsky performance status (KPS) score.Results There was 2 patients withdrew from chemotherapy due to serious adverse reactions related to apatinib in the observation group,and 1 patient stopped chemotherapy by himself;in the control group,2 patients were treated in other hospitals,and 1 patient changed chemotherapy regimen.There were 26 patients in each group who completed all treatment and evaluation.The ORR of patients in the observation group and the control group was 53.84% (14/26),23.08% (6/26),respectively;and the DCR of patients in the observation group and the control group was 92.31% (24/26) and 69.23% (18/26),respectively.The ORR and DCR of patients in the observation group were significantly higher than those in the control group(χ2=5.200,4.457;P<0.05).The median PFS of patients in the observation group was 8.9 months,and the median PFS of patients in the control group was 6.9 months;the median PFS of patients in the observation group was significantly longer than that in the control group(P<0.05).There was no significant difference in serum CA125 level of patients between the two groups before treatment (P>0.05);after treatment,the level of serum CA125 of patients in the two groups was significantly lower than that before treatment,and the level of serum CA125 of patients in the observation group was significantly lower than that in the control group (P<0.05).There was no significant difference in the KPS score of patients between the two groups before treatment (P>0.05);after treatment,the KPS score of patients in the two groups was significantly higher than that before treatment,and the KPS score of patients in the observation group was significantly higher than that in the control group (P<0.05).There was no significant difference in the incidences of gastrointestinal reaction,fatigue,hand-foot syndrome and anemia of patients between the two groups (P>0.05);the incidence of hypertension of patients in the observation group was significantly higher than that in the control group(χ2=0.002,P<0.05).Conclusion Apatinib combined with paclitaxel single drug chemotherapy can improve the clinical efficacy of patients with recurrent drug-resistant epithelial ovarian cancer.

参考文献/References:

[1] FERLAY J,COLOMBET M,SOERJOMATARAM I,et al.Cancer incidence and mortality patterns in Europe:estimates for 40 countries and 25 major cancers in 2018[J].Eur J Cancer,2018,103:356-387.
[2] CHIEN J,POOLE E.Ovarian cancer prevention,screening and early detection:report from the 11th biennial ovarian cancer research symposium[J].Int J Gynecol Cancer,2017,27(9S Suppl 5):S20-S22.
[3] ROJAS V,HIRSHFIELD K M,GANESAN S,et al.Molecular characterization of epithelial ovarian cancer:implications for diagnosis and treatment[J].Int J Mol Sci,2016,17(12):2113.
[4] GARZON S,LAGANà A S,CASARIN J,et al.Secondary and tertiary ovarian cancer recurrence:what is the best management[J].Gland Surg,2020,9(4):1118-1129.
[5] LHEUREUX S,OAKNIN A,GARG S,et al.EVOLVE:a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression[J].Clin Cancer Res,2020,26(16):4206-4215.
[6] 时佳琪,刘超,张艳桥,等.甲磺酸阿帕替尼治疗恶性肿瘤的临床不良反应分析[J].中国肿瘤临床,2018,45(4):191-195.
SHI J Q,LIU C,ZHANG Y J,et al.Analysis of clinical adverse reactions of apatinib for the treatment of malignant tumors[J].Chin Oncol Clin,2018,45(4):191-195.
[7] LI J,QIN S,XU J,et al.Randomized,double-blind,placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34 (13):1448-1454.
[8] GREGORY J,DIOGUARDI BURGIO M,CORRIAS G,et al.Evaluation of liver tumour response by imaging[J].JHEP Rep,2020,2(3):100100.
[9] SMITH TL,SARTO G,HELOW K,et al.Impact of change from CTCAE Version 3 to CTCAE Version 4 on urologic toxicity scores in prostate cancer-international journal of Radiation Oncology Biology Physics[J].Int J Radiat Oncol Biol Phys,2014,90(1):S419.
[10] MOR V,LALIBERTE L,MORRIS J N,et al.The karnofsky performance status scale.An examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[11] GRUNEWALD T,LEDERMANN J A.Targeted therapies for ovarian cancer[J].Best Pract Res Clin Obstet Gynaecol,2017,41:139-152.
[12] SUN H,XIAO M,LIU S,et al.Use of apatinib combined with pemetrexed for advanced ovarian cancer:a case report[J].Medicine (Baltimore),2018,97 (27):e11036
[13] GARZON S,LAGAN A S,CASARIN J,et al.Secondary and tertiary ovarian cancer recurrence:what is the best management?[J].Gland Surg,2020,9(4):1118-1129.
[14] LEE Y J,LEE I H,KIM Y J,et al.Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy[J].PLoS One,2018,13(9):e0203366.
[15] URUSKI P,SEPETOWSKA A,KONIECZNA C,et al.Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro[J].Cell Mol Biol Lett,2021,26(1):44.
[16] WANG S,YAO Y,YAO M,et al.Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathway[J].Biochem Biophys Res Commun,2018,503(3):1605-1609.
[17] HE M,ZHU J,YU N,et al.The superior antitumor effect of self-assembled paclitaxel nanofilaments for lung cancer cells[J].Curr Drug Deliv,2019,16(2):171-178.
[18] ROVILLO G,RAVELLI A,POLOM K,et al.Apatinib:a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer[J].Cancer Lett,2016,372(2):189-191.
[19] 王婷,马惠文,王东林,等.甲磺酸阿帕替尼片单药三线治疗VEGFR-2高表达晚期非鳞NSCLC患者的近期疗效和安全性体会[J].实用肿瘤杂志,2018,33(5):410-415.
WANG T,MA H W,WANG D L,et al.Short-term efficacy and safety of apatinib mesylate tablets in third-line monotherapy for advanced non-squamous NSCLC with high VEGFR-2 expression[J].J Pract Oncol,2018,33(5):410-415.
[20] DING J,CHENG XY,LIU S,et al.Apatinib exerts anti-tumour effects on ovarian cancer cells[J].Gynecol Oncol,2019,153(1):165-174.
[21] ZHANG J,LI A,JIANG Q,et al.Efficacy and safety of apatinib treatment in platinum-resistant recurrent epithelial ovarian cancer:a real world study[J].Drug Des Devel Ther,2019,13:3913-3918.
[22] 褚超男,黄琪.阿帕替尼治疗复发性卵巢癌的疗效及安全性评价[J].中国新药杂志,2020,29(3):299-302.
CHU C N,HANG Q.Efficacy and safety of apatinib in the chemotherapy of recurrent platinum resistant ovarian cance[J].Chin J New Drugs,2020,29(3):299-302.
[23] MIAO M,DENG G,LUO S,et al.A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J].Gynecol Oncol,2018,148(2):286-290.

相似文献/References:

[1]叶林华,袁苏徐.紫杉醇联合卡培他滨治疗晚期胃癌疗效观察[J].新乡医学院学报,2011,28(01):102.
[2]张少华,刘凯歌,郑建云,等.上皮性卵巢癌中癌胚抗原相关细胞黏附分子1和CD105的表达[J].新乡医学院学报,2012,29(11):834.
[3]沈慧敏,梁武凤,杨 君,等.人附睾蛋白4、溶血磷脂酸和糖类抗原125联合检测在上皮性卵巢癌诊断中的价值[J].新乡医学院学报,2014,31(11):922.[doi:10.7683/xxyxyxb.2014.11.016]
[4]丁 锋,张清会.厄洛替尼联合紫杉醇和顺铂治疗晚期非小细胞肺癌疗效观察[J].新乡医学院学报,2018,35(6):513.[doi:10.7683/xxyxyxb.2018.06.016]
 DING Feng,ZHANG Qing-hui.Effect of erlotinib combined with paclitaxel and cisplatin in treatment of advanced non-small cell lung cancer[J].Journal of Xinxiang Medical University,2018,35(4):513.[doi:10.7683/xxyxyxb.2018.06.016]
[5]常 伟,丁 敏,周建华,等.曲妥珠单抗联合紫杉醇治疗人表皮生长因子受体-2过表达转移性乳腺癌的疗效和安全性评价[J].新乡医学院学报,2018,35(6):517.[doi:10.7683/xxyxyxb.2018.06.017]
 CHANG Wei,DING Min,ZHOU Jian-hua,et al.Efficacy and safety of trastuzumab combined with paclitaxel for treatment of human epidermal growth factor receptor-2 overexpressing metastatic breast cancer patients[J].Journal of Xinxiang Medical University,2018,35(4):517.[doi:10.7683/xxyxyxb.2018.06.017]
[6]李小峰,孙新宇,张 慧.曲妥珠单抗联合紫杉醇和卡铂治疗人表皮生长因子受体-2阳性乳腺癌的疗效及其对心功能的影响[J].新乡医学院学报,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]
 LI Xiaofeng,SUN Xinyu,ZHANG Hui.Effect of trastuzumab combined with paclitaxel and carboplatin in the treatment of patients with human epidermal growth factor receptor-2-positive breast cancer and its effect on cardiac function[J].Journal of Xinxiang Medical University,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]

更新日期/Last Update: 2022-04-05